Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals.
Sarah E Smith-JeffcoatJessica E BiddleH Keipp TalbotKerry Grace MorriseyMelissa S StockwellYvonne MaldonadoHuong Q McLeanKatherine D EllingsonNatalie M BowmanEdwin Jose AsturiasAlexandra M MellisSheroi JohnsonHannah L KirkingMelissa A R RolfesVanessa OlivoLori MerrillSteph Battan-WraithEllen D SanoSon H McLarenCelibell Y VargasSara GoodmanClea C SarnquistPrasanthi GovindaranjanJoshua G PetrieEdward A BelongiaKarla LedezmaKathleen PryorKaren LutrickAyla BullockAmy YangQuenla HaehnelSuchitra RaoYuwei ZhuJonathan SchmitzKimberly HartCarlos G GrijalvaPhillip P SalvatorePublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Individuals who completed N/R experienced fewer symptoms and lower VL but were more likely to have rebound compared to untreated individuals. Providers should still prescribe N/R, when indicated, and communicate possible increased rebound risk to patients.